The diseases for which IFN-α therapy was indicated in these patients included hepatitis C in 6 patients, malignant melanoma in 2, hepatitis B in 1, essential thrombocytosis in 1, and chronic myelocytic leukemia in 1. Here, IFNA1 is linked to hepatitis C virus infection.